News
Needham Reiterates Buy on Merus, Maintains $66 Price Target
11 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
8 Apr 24
Biotech, News, General
Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69
28 Mar 24
News, Price Target, Initiation, Analyst Ratings
Needham Maintains Buy on Merus, Raises Price Target to $66
7 Mar 24
News, Price Target, Analyst Ratings
Needham Maintains Buy on Merus, Raises Price Target to $65
4 Mar 24
News, Price Target, Analyst Ratings
On Wednesday February 28, 2024, Merus Reported Q4 Adjusted. EPS $(1.09) Misses $(0.74) Estimate, Sales $8.94M Miss $10.13M Estimate
29 Feb 24
Earnings, News
HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $65
29 Feb 24
News, Price Target, Analyst Ratings
Stifel Maintains Buy on Merus, Raises Price Target to $65
29 Feb 24
News, Price Target, Analyst Ratings
BMO Capital Maintains Outperform on Merus, Raises Price Target to $58
29 Feb 24
News, Price Target, Analyst Ratings
As Of December 31, 2023, Merus Had $411.7M Cash, Cash Equivalents And Marketable Securities
28 Feb 24
Earnings, News
Press releases
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
8 Apr 24
Press Releases
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
5 Mar 24
Health Care, Press Releases
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
4 Mar 24
News, Press Releases
Merus to Participate in Upcoming Investor Conferences
31 Jan 24
News, Press Releases